

Avraham Eisbruch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10797789/publications.pdf>

Version: 2024-02-01

196
papers

19,482
citations

13087

68
h-index

11303

136
g-index

200
all docs

200
docs citations

200
times ranked

12033
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Normal Tissue Complication Probability Models in the Clinic. International Journal of Radiation Oncology Biology Physics, 2010, 76, S10-S19.	0.4	1,376
2	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Tj ETQq0 0 0 rgBT / Overlock 10 T	0.3	879
3	Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. International Journal of Radiation Oncology Biology Physics, 1999, 45, 577-587.	0.4	840
4	Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2001, 50, 695-704.	0.4	661
5	CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiotherapy and Oncology, 2003, 69, 227-236.	0.3	611
6	Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT?. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1425-1439.	0.4	577
7	EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer. Journal of Clinical Oncology, 2008, 26, 3128-3137.	0.8	559
8	Radiotherapy Doseâ€“Volume Effects on Salivary Gland Function. International Journal of Radiation Oncology Biology Physics, 2010, 76, S58-S63.	0.4	462
9	Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 23-28.	0.4	438
10	Intensity-Modulated Radiotherapy of Head and Neck Cancer Aiming to Reduce Dysphagia: Early Doseâ€“Effect Relationships for the Swallowing Structures. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1289-1298.	0.4	434
11	Prevention and Treatment of Dysphagia and Aspiration After Chemoradiation for Head and Neck Cancer. Journal of Clinical Oncology, 2006, 24, 2636-2643.	0.8	358
12	Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1117-1126.	0.4	344
13	Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22). International Journal of Radiation Oncology Biology Physics, 2010, 76, 1333-1338.	0.4	336
14	Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number. Journal of Clinical Oncology, 2008, 26, 3138-3146.	0.8	329
15	Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiotherapy and Oncology, 2006, 79, 15-20.	0.3	323
16	Quality of life after parotid-sparing IMRT for head-and-neck cancer: A prospective longitudinal study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 61-70.	0.4	321
17	Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results. Journal of Clinical Oncology, 2010, 28, 2732-2738.	0.8	305
18	Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. International Journal of Radiation Oncology Biology Physics, 2004, 59, 28-42.	0.4	297

#	ARTICLE	IF	CITATIONS
19	Tobacco Use in Human Papillomavirus-Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence. <i>Clinical Cancer Research</i> , 2010, 16, 1226-1235.	3.2	271
20	Lack of Osteoradionecrosis of the Mandible After Intensity-Modulated Radiotherapy for Head and Neck Cancer: Likely Contributions of Both Dental Care and Improved Dose Distributions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 396-402.	0.4	263
21	Single-Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm. <i>Journal of Clinical Oncology</i> , 2006, 24, 593-598.	0.8	240
22	Radiation Therapy and Hearing Loss. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, S50-S57.	0.4	216
23	Chemo-IMRT of Oropharyngeal Cancer Aiming to Reduce Dysphagia: Swallowing Organs Late Complication Probabilities and Dosimetric Correlates. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e93-e99.	0.4	216
24	Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 1143-1169.	0.8	216
25	Dose-Effect Relationships for the Submandibular Salivary Glands and Implications for Their Sparing by Intensity Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 373-382.	0.4	212
26	Intensity-modulated radiation therapy for head and neck cancer: Emphasis on the selection and delineation of the targets. <i>Seminars in Radiation Oncology</i> , 2002, 12, 238-249.	1.0	209
27	Treatment of late sequelae after radiotherapy for head and neck cancer. <i>Cancer Treatment Reviews</i> , 2017, 59, 79-92.	3.4	201
28	The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 660-669.	0.4	189
29	Radiation Dose-Volume Effects in the Larynx and Pharynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, S64-S69.	0.4	189
30	Parotid gland sparing in patients undergoing bilateral head and neck irradiation: Techniques and early results. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 36, 469-480.	0.4	188
31	Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 559-568.	0.4	182
32	Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1393-1402.	0.4	176
33	Salivary Gland Sparing and Improved Target Irradiation by Conformal and Intensity Modulated Irradiation of Head and Neck Cancer. <i>World Journal of Surgery</i> , 2003, 27, 832-837.	0.8	173
34	The Lessons of QUANTEC: Recommendations for Reporting and Gathering Data on Dose-Volume Dependencies of Treatment Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, S155-S160.	0.4	171
35	Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: Initial report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 725-731.	0.4	169
36	Toxicities Affecting Quality of Life After Chemo-IMRT of Oropharyngeal Cancer: Prospective Study of Patient-Reported, Observer-Rated, and Objective Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 935-940.	0.4	167

#	ARTICLE	IF	CITATIONS
37	Parotid Gland Function After Radiotherapy: The Combined Michigan and Utrecht Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 449-453.	0.4	155
38	A Pilot Study of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3116-3123.	0.8	154
39	Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 445-453.	0.4	148
40	A Feasibility Study of Parametric Response Map Analysis of Diffusion-Weighted Magnetic Resonance Imaging Scans of Head and Neck Cancer Patients for Providing Early Detection of Therapeutic Efficacy. <i>Translational Oncology</i> , 2009, 2, 184-190.	1.7	146
41	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. <i>Head and Neck</i> , 2016, 38, E2151-8.	0.9	146
42	Reducing Xerostomia After Chemo-IMRT for Head-and-Neck Cancer: Beyond Sparing the Parotid Glands. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1007-1014.	0.4	145
43	Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1395-1399.	0.4	143
44	How should we measure and report radiotherapy-induced xerostomia?. <i>Seminars in Radiation Oncology</i> , 2003, 13, 226-234.	1.0	135
45	Radiation Concurrent With Gemcitabine for Locally Advanced Head and Neck Cancer: A Phase I Trial and Intracellular Drug Incorporation Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 792-799.	0.8	133
46	Early Prediction of Outcome in Advanced Head-and-Neck Cancer Based on Tumor Blood Volume Alterations During Therapy: A Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1287-1290.	0.4	119
47	Nonendemic HPV-Positive Nasopharyngeal Carcinoma: Association With Poor Prognosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 580-588.	0.4	119
48	Infiltrating lymphocytes and human papillomavirus 16-associated oropharyngeal cancer. <i>Laryngoscope</i> , 2012, 122, 121-127.	1.1	113
49	Correlation of Cellular Immunity With Human Papillomavirus 16 Status and Outcome in Patients With Advanced Oropharyngeal Cancer. <i>JAMA Otolaryngology</i> , 2010, 136, 1267.	1.5	111
50	HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. <i>Head and Neck</i> , 2010, 32, 562-567.	0.9	109
51	Intensity-Modulated Radiation Therapy for Head and Neck Carcinoma. <i>Oncologist</i> , 2007, 12, 555-564.	1.9	106
52	Response to Therapy and Outcomes in Oropharyngeal Cancer Are Associated With Biomarkers Including Human Papillomavirus, Epidermal Growth Factor Receptor, Gender, and Smoking. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S109-S111.	0.4	101
53	Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. <i>Laryngoscope</i> , 2009, 119, 1510-1517.	1.1	94
54	Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. <i>Radiotherapy and Oncology</i> , 2008, 89, 13-18.	0.3	93

#	ARTICLE	IF	CITATIONS
55	High-Risk Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 1320.	1.2	93
56	Strategies to reduce long-term postchemoradiation dysphagia in patients with head and neck cancer: An evidence-based review. <i>Head and Neck</i> , 2014, 36, 431-443.	0.9	93
57	IMRT for head and neck cancer: reducing xerostomia and dysphagia. <i>Journal of Radiation Research</i> , 2016, 57, i69-i75.	0.8	93
58	Can IMRT or Brachytherapy Reduce Dysphagia Associated With Chemoradiotherapy of Head and Neck Cancer? The Michigan and Rotterdam Experiences. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S40-S42.	0.4	91
59	Anatomical changes in the pharyngeal constrictors after chemo-irradiation of head and neck cancer and their dose-effect relationships: MRI-based study. <i>Radiotherapy and Oncology</i> , 2009, 93, 510-515.	0.3	89
60	Aspiration pneumonia after chemo-intensity modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. <i>Head and Neck</i> , 2014, 36, 120-125.	0.9	84
61	Long-Term Quality of Life After Swallowing and Salivary-Sparing Chemo-Intensity Modulated Radiation Therapy in Survivors of Human Papillomavirus-Related Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 925-933.	0.4	83
62	Clinical Practice Guidance for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 725-733.	0.4	80
63	Partial irradiation of the parotid gland. <i>Seminars in Radiation Oncology</i> , 2001, 11, 234-239.	1.0	78
64	A Comparison of Dose-Response Models for the Parotid Gland in a Large Group of Head-and-Neck Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1259-1265.	0.4	77
65	Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. <i>Head and Neck</i> , 2012, 34, 1727-1733.	0.9	75
66	Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. <i>Radiotherapy and Oncology</i> , 2018, 126, 68-74.	0.3	74
67	Organ-sparing radiation therapy for head and neck cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 639-648.	12.5	73
68	Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 246-253.	1.1	73
69	Radiosensitization produced in vivo by once- vs. twice-weekly 2-fluoro-2-deoxycytidine (gemcitabine). <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 785-791.	0.4	72
70	Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 234-239.	0.8	68
71	Decreased 3D observer variation with matched CT-MRI, for target delineation in Nasopharynx cancer. <i>Radiation Oncology</i> , 2010, 5, 21.	1.2	67
72	Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 354-361.	0.4	63

#	ARTICLE	IF	CITATIONS
73	Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 513-519.	0.8	62
74	Prognostic Value of Positron Emission Tomography Using F-18-Fluorodeoxyglucose in Patients with Cervical Cancer Undergoing Radiotherapy. <i>Gynecologic Oncology</i> , 2002, 84, 289-295.	0.6	61
75	An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in	1.6	59
76	Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients. <i>Cancer Detection and Prevention</i> , 2003, 27, 305-310.	2.1	58
77	The big data effort in radiation oncology: Data mining or data farming?. <i>Advances in Radiation Oncology</i> , 2016, 1, 260-271.	0.6	58
78	Recommended Patient-Reported Core Set of Symptoms to Measure in Head and Neck Cancer Treatment Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	57
79	Reducing Xerostomia by IMRT: What May, and May Not, Be Achieved. <i>Journal of Clinical Oncology</i> , 2007, 25, 4863-4864.	0.8	56
80	Intensity-modulated radiotherapy of head-and-neck cancer: encouraging early results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 1-3.	0.4	55
81	Balancing Risk and Reward in Target Delineation for Highly Conformal Radiotherapy in Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2009, 19, 43-52.	1.0	55
82	Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1413-1418.	0.4	54
83	Physical Models and Simpler Dosimetric Descriptors of Radiation Late Toxicity. <i>Seminars in Radiation Oncology</i> , 2007, 17, 108-120.	1.0	52
84	Skin cancer of the head and neck with gross or microscopic perineural involvement: Patterns of failure. <i>Radiotherapy and Oncology</i> , 2016, 120, 81-86.	0.3	50
85	Irradiation of paranasal sinus tumors, a delineation and dose comparison study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 120-127.	0.4	46
86	Safety considerations for IMRT: Executive summary. <i>Practical Radiation Oncology</i> , 2011, 1, 190-195.	1.1	46
87	Changes in Global Function and Regional Ventilation and Perfusion on SPECT During the Course of Radiotherapy in Patients With Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e631-e638.	0.4	46
88	Radiation-induced carotid artery lesions. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 699-710.	1.0	46
89	Early Changes in Serial CBCT-Measured Parotid Gland Biomarkers Predict Chronic Xerostomia After Head and Neck Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1319-1329.	0.4	43
90	Utility of Pretreatment Mean Apparent Diffusion Coefficient and Apparent Diffusion Coefficient Histograms in Prediction of Outcome to Chemoradiation in Head and Neck Squamous Cell Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2012, 36, 131-137.	0.5	42

#	ARTICLE	IF	CITATIONS
91	Clinical aspects of IMRT for head-and-neck cancer. <i>Medical Dosimetry</i> , 2002, 27, 99-104.	0.4	41
92	Intensity-modulated radiation therapy in the treatment of head and neck cancer. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 34-39.	4.3	41
93	Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. <i>Head and Neck</i> , 2016, 38, E1086-96.	0.9	41
94	Matted nodes: High distant metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E805-14.	0.9	39
95	Organ-Sparing in Radiotherapy for Head-and-Neck Cancer: Improving Quality of Life. <i>Seminars in Radiation Oncology</i> , 2018, 28, 46-52.	1.0	38
96	Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2014, 36, n/a-n/a.	0.9	37
97	Patient-Reported Voice and Speech Outcomes After Whole-Neck Intensity Modulated Radiation Therapy and Chemotherapy for Oropharyngeal Cancer: Prospective Longitudinal Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 973-980.	0.4	37
98	Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 32-38.	0.3	36
99	Future Issues in Highly Conformal Radiotherapy for Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1009-1013.	0.8	36
100	Impact of xerostomia on dysphagia after chemotherapy-intensity modulated radiotherapy for oropharyngeal cancer: Prospective longitudinal study. <i>Head and Neck</i> , 2016, 38, E1605-12.	0.9	36
101	Ipsilateral parotid sparing study in head and neck cancer patients who receive radiation therapy. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 1996, 81, 642-648.	1.6	35
102	Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 184-190.	0.9	35
103	Dysphagia and aspiration following chemo-irradiation of head and neck cancer: major obstacles to intensification of therapy. <i>Annals of Oncology</i> , 2004, 15, 363-364.	0.6	34
104	Head and neck squamous cell carcinoma of unknown primary: Neck dissection and radiotherapy or definitive radiotherapy. <i>Head and Neck</i> , 2014, 36, 1589-1595.	0.9	34
105	Normal Tissue Anatomy for Oropharyngeal Cancer: Contouring Variability and Its Impact on Optimization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e245-e249.	0.4	33
106	Efficacy of Induction Selection Chemotherapy vs Primary Surgery for Patients With Advanced Oral Cavity Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 134.	1.2	33
107	Evaluating and Reporting Dysphagia in Trials of Chemoirradiation for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 727-733.	0.4	32
108	Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2013, 49, 283-286.	0.8	32

#	ARTICLE	IF	CITATIONS
109	Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 75-81.	0.3	32
110	Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 355.	1.2	32
111	Amifostine in the Treatment of Head and Neck Cancer: Intravenous Administration, Subcutaneous Administration, or None of the Above. <i>Journal of Clinical Oncology</i> , 2011, 29, 119-121.	0.8	30
112	Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. <i>Head and Neck</i> , 2013, 35, 1083-1090.	0.9	30
113	Predictors of severe long-term toxicity after re-irradiation for head and neck cancer. <i>Oral Oncology</i> , 2016, 60, 32-40.	0.8	30
114	Lhermitte Sign After Chemo-IMRT of Head-and-Neck Cancer: Incidence, Doses, and Potential Mechanisms. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1528-1533.	0.4	28
115	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 857-864.	0.9	28
116	The influence of pre-radiation salivary flow rates and radiation dose on parotid salivary gland dysfunction in patients receiving radiotherapy for head and neck cancers. <i>Special Care in Dentistry</i> , 1998, 18, 102-108.	0.4	27
117	Tumor Volumes and Prognosis in Laryngeal Cancer. <i>Cancers</i> , 2015, 7, 2236-2261.	1.7	27
118	E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2723-2729.	3.2	25
119	The prevention and treatment of radiotherapy-induced xerostomia. <i>Seminars in Radiation Oncology</i> , 2003, 13, 302-308.	1.0	24
120	Parameters Associated With Mandibular Osteoradionecrosis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1276-1280.	0.6	24
121	Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2013, 35, 1323-1330.	0.9	23
122	Volumetric ¹⁸ F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy. <i>Head and Neck</i> , 2019, 41, 366-373.	0.9	23
123	Automatic recognition and analysis of metal streak artifacts in head and neck computed tomography for radiomics modeling. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 10, 49-54.	1.2	23
124	Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 137, 167-174.	0.3	23
125	Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. <i>Head and Neck</i> , 2014, 36, 617-623.	0.9	22
126	Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2877-2894.	0.8	22

#	ARTICLE	IF	CITATIONS
127	Commentary: Induction Chemotherapy for Head and Neck Cancer: Hypothesis-Based Rather Than Evidence-Based Medicine. <i>Oncologist</i> , 2007, 12, 975-977.	1.9	21
128	Double-blind placebo-controlled multicenter phase II trial to evaluate Dâ€m-methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer. <i>Head and Neck</i> , 2018, 40, 1375-1388.	0.9	21
129	Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. <i>Laryngoscope</i> , 2016, 126, E292-E299.	1.1	20
130	Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards. <i>Advances in Radiation Oncology</i> , 2017, 2, 503-514.	0.6	20
131	Delineating Neck Targets for Intensity- Modulated Radiation Therapy of Head and Neck Cancer. , 2007, 40, 193-207.		19
132	Predictive Models to Determine Clinically Relevant Deviations in Delivered Dose for Head and Neck Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, e422-e431.	1.1	19
133	The future of induction chemotherapy for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2012, 48, 1065-1067.	0.8	18
134	Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review. <i>Cancers</i> , 2021, 13, 1254.	1.7	18
135	Spinal cord dose from standard head and neck irradiation: implications for three-dimensional treatment planning. <i>Radiotherapy and Oncology</i> , 1998, 47, 185-189.	0.3	17
136	Positron emission tomographyâ€CT prediction of occult nodal metastasis in recurrent laryngeal cancer. <i>Head and Neck</i> , 2017, 39, 980-987.	0.9	17
137	Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 969-977.	0.4	17
138	Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2019, 78, 42-51.	3.4	17
139	Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16â€ High Risk Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1118.	1.3	17
140	Feasibility of Non-invasive Brain Modulation for Management of Pain Related to Chemoradiotherapy in Patients with Advanced Head and Neck Cancer. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 466.	1.0	16
141	Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era. <i>Cancer</i> , 2019, 125, 68-78.	2.0	16
142	Design and analysis of an immobilization and repositioning system for treatment of neck malignancies. <i>Medical Dosimetry</i> , 1997, 22, 293-297.	0.4	15
143	Recovery of salivary epidermal growth factor in parotid saliva following parotid sparing radiation therapy: a proof-of-principle study. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2011, 111, 64-70.	1.6	15
144	Single or multi-channel vaginal cuff high-dose-rate brachytherapy: Is replanning necessary prior to each fraction?. <i>Practical Radiation Oncology</i> , 2014, 4, 20-26.	1.1	15

#	ARTICLE	IF	CITATIONS
145	Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor. <i>Head and Neck</i> , 2015, 37, 8-11.	0.9	15
146	Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation. <i>Oral Oncology</i> , 2016, 54, 68-74.	0.8	15
147	Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 111, 104853.	0.8	15
148	Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics. <i>Radiotherapy and Oncology</i> , 2020, 148, 30-37.	0.3	15
149	Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation. <i>Oral Oncology</i> , 2021, 121, 105332.	0.8	15
150	Planned Early Neck Dissection Before Radiation for Persistent Neck Nodes After Induction Chemotherapy. <i>Laryngoscope</i> , 1997, 107, 1129-1137.	1.1	14
151	Squamous Cell Carcinoma of the Tongue During Pregnancy: A Case Report and Review of the Literature. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016, 74, 2557-2566.	0.5	14
152	Investigating the clinical significance of body composition changes in patients undergoing chemoradiation for oropharyngeal cancer using analytic morphomics. <i>SpringerPlus</i> , 2016, 5, 429.	1.2	13
153	Should patients with laryngeal small cell neuroendocrine carcinoma receive prophylactic cranial irradiation?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2925-2930.	0.8	12
154	Bromodeoxyuridine Alternating With Radiation for Advanced Uterine Cervix Cancer: A Phase I and Drug Incorporation Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 31-31.	0.8	11
155	Methods for Reducing Normal Tissue Complication Probabilities in Oropharyngeal Cancer: Dose Reduction or Planning Target Volume Elimination. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 645-652.	0.4	11
156	Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 313.	1.2	11
157	CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 155, 174-181.	0.3	11
158	MRI to delineate the gross tumor volume of nasopharyngeal cancers: which sequences and planes should be used?. <i>Radiology and Oncology</i> , 2014, 48, 323-330.	0.6	9
159	Radiotherapy in the management of glottic squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 3558-3567.	0.9	9
160	Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. <i>Cancers</i> , 2022, 14, 2587.	1.7	9
161	Temporal Feature Extraction from DCE-MRI to Identify Poorly Perfused Subvolumes of Tumors Related to Outcomes of Radiation Therapy in Head and Neck Cancer. <i>Tomography</i> , 2016, 2, 341-352.	0.8	8
162	Restoration of the Orbital Aesthetic Subunit with the Thoracodorsal Artery System of Flaps in Patients Undergoing Radiation Therapy. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2013, 74, 279-285.	0.4	7

#	ARTICLE	IF	CITATIONS
163	Phase I Trial of Radiotherapy Concurrent with Twice-Weekly Gemcitabine for Head and Neck Cancer: Translation From Preclinical Investigations Aiming to Improve the Therapeutic Ratio. <i>Translational Oncology</i> , 2014, 7, 479-483.	1.7	7
164	Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 170-176.	0.4	7
165	Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 995-997.	1.1	7
166	Real-Time Quantitative Assessment of Accuracy and Precision of Blood Volume Derived from DCE-MRI in Individual Patients during a Clinical Trial. <i>Tomography</i> , 2019, 5, 61-67.	0.8	7
167	Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. <i>Head and Neck</i> , 2020, 42, 1728-1737.	0.9	6
168	Testing new chemoradiation regimens for head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 5-6.	0.4	5
169	Function, Muscles, and Sparing by IMRT for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 577-578.	0.4	5
170	Impact of xerostomia and dysphagia on health-related quality of life for head and neck cancer patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 361-371.	0.6	5
171	Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 625-630.	1.1	5
172	Early MRI Blood Volume Changes in Constrictor Muscles Correlate With Postradiation Dysphagia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 566-573.	0.4	5
173	Contemporary management of the neck in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2021, 43, 1949-1963.	0.9	4
174	What a surgeon needs to know about radiation. <i>Annals of Surgical Oncology</i> , 1997, 4, 516-522.	0.7	3
175	Delineating Neck Targets for Intensity-Modulated Radiation Therapy of Head and Neck Cancer. <i>Frontiers of Radiation Therapy and Oncology</i> , 2011, 43, 255-270.	1.4	3
176	Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. <i>JAMA Oncology</i> , 2017, 3, 414.	3.4	3
177	<sc>Long-term</sc> neck and shoulder function among survivors of oropharyngeal squamous cell carcinoma treated with chemoradiation as assessed with the neck dissection impairment index. <i>Head and Neck</i> , 2021, 43, 1621-1628.	0.9	2
178	Post-Radiation Dysphagia. <i>Medical Radiology</i> , 2008, , 67-79.	0.0	2
179	Conformal Therapy and Intensity-Modulated Radiation Therapy. , 2012, , 287-316.		2
180	Reducing radiation-induced xerostomia with highly conformal radiotherapy techniques. <i>The Journal of Supportive Oncology</i> , 2005, 3, 201-2.	2.3	2

#	ARTICLE	IF	CITATIONS
181	Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel <sc>Bcl-2</sc> inhibitor. Head and Neck, 2022, , .	0.9	2
182	Clinical heterogeneity and tumor control probability. Acta Oncologica, 2010, 49, 1385-1387.	0.8	1
183	Neurologic late effects associated with radiologic evidence of vertebral osteoradionecrosis after salvage laryngectomy: A syndrome associated with survivors of laryngeal and hypopharyngeal cancer. Head and Neck, 2016, 38, 1187-1193.	0.9	1
184	Intensity-Modulated and Image-Guided Radiation Therapy. , 2016, , 294-324.e5.		1
185	Can xerostomia be further reduced by sparing parotid stem cells?. Annals of Translational Medicine, 2016, 4, S16-S16.	0.7	1
186	Stricter Postoperative Oropharyngeal Cancer Radiotherapy Normal Tissue Dose Constraints Are Feasible. Practical Radiation Oncology, 2022, , .	1.1	1
187	In Reply to Ren et al. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1214.	0.4	0
188	When is definitive radiotherapy the preferred treatment for head and neck squamous cell carcinoma?. European Archives of Oto-Rhino-Laryngology, 2015, 272, 2583-2586.	0.8	0
189	Doing the Right Thing for the Wrong Reason. International Journal of Radiation Oncology Biology Physics, 2017, 99, 596-597.	0.4	0
190	Utilizing skin sparing technique in HN VMAT treatment planning. Medical Dosimetry, 2019, 44, 155-158.	0.4	0
191	Improving the Quality of Life of Patients with Head and Neck Cancer by Highly Conformal Radiotherapy. Medical Radiology, 2009, , 145-153.	0.0	0
192	Normal Tissue Complications and Protection in Head and Neck Cancer Patients. , 2011, , 613-628.		0
193	Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia. Medical Radiology, 2014, , 167-188.	0.0	0
194	Normal Tissue Complications and Protection in Head and Neck Cancer Patients. , 2016, , 753-767.		0
195	Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials. Clinical and Translational Radiation Oncology, 2022, 33, 30-36.	0.9	0
196	Head and neck cancer: advances in radiation treatment. MedGenMed: Medscape General Medicine, 2002, 4, 16.	0.2	0